[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-medullary-carcinoma-rmc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-medullary-carcinoma-rmc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":4,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":4,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":14,"phases":4,"briefSummary":15,"conditions":16,"keywords":4,"overallStatus":19,"whyStopped":4,"lastUpdateSubmitDate":20,"lastUpdatePostDateStruct":21,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":24,"locationsCount":4},"100631594",false,"NCT07502716","Compassionate Use of Ubamatamab","Eligibility will be determined during the application review process.","EXPANDED_ACCESS","Provide Compassionate Use of Ubamatamab",[17,18],"Renal Medullary Carcinoma (RMC)","Epithelioid Sarcoma","AVAILABLE","2026-03-24",{"date":22,"type":23},"2026-03-31","ACTUAL",{"name":25,"class":26},"Regeneron Pharmaceuticals","INDUSTRY",""]